Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial

N. Thomson, R. Niven, C. Prys-Picard, P. Corris, R. Olivenstein, H. C. Siersted, I. Pavord, G. Cox, D. McCormack, A. Rubin, M. Laviolette (Glasgow, Manchester, Newcastle upon Tyne, Leicester, United Kingdom; Galveston, United States Of America; Montreal, Hamilton, Ontario, Quebec, Canada; , Denmark; Santa Casa de Porto Alegre, Brazil)

Source: Annual Congress 2010 - Aspects of severe asthma
Session: Aspects of severe asthma
Session type: E-Communication Session
Number: 5484
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Thomson, R. Niven, C. Prys-Picard, P. Corris, R. Olivenstein, H. C. Siersted, I. Pavord, G. Cox, D. McCormack, A. Rubin, M. Laviolette (Glasgow, Manchester, Newcastle upon Tyne, Leicester, United Kingdom; Galveston, United States Of America; Montreal, Hamilton, Ontario, Quebec, Canada; , Denmark; Santa Casa de Porto Alegre, Brazil). Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial. Eur Respir J 2010; 36: Suppl. 54, 5484

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011


Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016


Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016


Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016

Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS)
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017



Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA
Source: International Congress 2014 – Paediatric asthma: what is new for the clinician?
Year: 2014


Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018



Characteristics of severe asthmatics treated with omalizumab, mepolizumab or no biotherapy. Data from the Belgian Severe Asthma Registry (BSAR).
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014

Tiotropium for uncontrolled asthma (a meta-analysis)
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013



Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial
Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Year: 2009

A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

U-BIOPRED: Clinical characteristics of children with severe asthma (SA) and severe pre-school wheeze (SPSW)
Source: International Congress 2014 – More paediatric asthma
Year: 2014